Sign up
Pharma Capital

VentriPoint Diagnostics names healthcare professional as new head of sales for North America

"Ventripoint is an impressive company with innovative products to improve patient cardiac diagnosis and care," added McPhedra
1515610057_Heart-cells.jpg
VentriPoint has developed a suite of applications for all major heart diseases

Heart analysis firm VentriPoint Diagnostics Ltd (CVE:VPT) has hired health care industry professional David McPhedran as director of sales for North America with immediate effect.

"He has a successful track record in establishing and managing sales teams for imaging products in the North American marketplace," said Desmond Hirson, president of Ventripoint.

"Ventripoint is an impressive company with innovative products to improve patient cardiac diagnosis and care," added McPhedran.

"I have engaged numerous cardiologists across Canada and can report that they are very interested in Ventripoint's technology as it helps to address the need for affordable, accurate cardiac measurement tools."

McPhedran's  CV includes director of sales for imaging in Western Canada for Siemens Healthcare, where his team achieved sales targets of $35mln a year.

He has also worked for Becton Dickinson and Johnson & Johnson in sales and marketing.

Shares eased  1.47% to C$0.34.

Giles_55af4ddca6481.jpg
Why Invest In VentriPoint Diagnostics? Read More Here

Register here to be notified of future VPT Company articles
View full VPT profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.